Program


July 10

Time Session Chairperson Speaker Title
18:00-18:10 Welcome Address
18:10-19:30 Keynote Dr. Shaw
Dr. Mano
Dr. Hiroyuki Mano
(National Cancer Center Research Institute)
TBD
Dr. Alice T. Shaw
(Massachusetts General Hospital)
TBD
19:50-21:50 Welcome Party

July 11

Time Session Chairperson Speaker Title
8:30-10:00 1. Personalized treatment strategies in lung cancer Dr. Drilon
Dr. Goto
Dr. Shinji Kohsaka
(The University of Tokyo)
Application of a high-throughput functional evaluation of variants of unknown significance to personalized medicine
Dr. Alexander E. Drilon
(Memorial Sloan Kettering Cancer Center)
TBD
Dr. Koichi Goto
(National Cancer Center Hospital East)
Development of a Nationwide Genomic Screening Project (LC-SCRUM-Japan) for the Establishment of Precision Medicine in Lung Cancer
10:00-10:20 Break
10:20-11:50 2. Latest advances in small cell lung cancer and mesothelioma Dr. Rudin
Dr. Aburatani
Dr. Charles M. Rudin
(Memorial Sloan Kettering Cancer Center)
Latest advances in small cell lung cancer
Dr. Hiroyuki Aburatani
(The University of Tokyo)
Integrated genomic analysis of malignant pleural mesothelioma
Dr. Shoutaro Tsuji
(Kanagawa Cancer Center)
Development of precise diagnosis with a new mesothelioma marker, sialylated HEGI
11:50-12:50 Lunch and Poster View
12:50-14:20 Poster Presentation
14:20-15:50 3. Targeting KRAS-mutant lung cancer Dr. Skoulidis
Dr. Nagase
Dr. Ferdinandos Skoulidis
(The University of Texas MD Anderson Cancer Center)
TBD
Dr. Hiromichi Ebi
(Aichi Cancer Center)
Combination therapies targeting KRAS mutant lung cancer
Dr. Hiroki Nagase
(Chiba Cancer Center Research Institute)
Targeting the RAS gene against cancer (tentative)
15:50-16:10 Break
16:10-17:40 4. Overcoming resistance to targeted therapies in lung cancer Dr. Lovly
Dr. Takahashi
Dr. Takashi Takahashi
(Nagoya University Graduate School of Medicine)
ROR1: An Achilles Heel of Lung Cancer (tentative)
Dr. Christine M. Lovly
(Vanderbilt University Medical Center)
Resistance to EGFR and ALK blockade (tentative)
Dr. Ryohei Katayama
(Cancer Chemotherapy Center of JFCR)
Drug repurposing: overcoming the acquired resistance with other target inhibitor (tentative)
18:00-19:00 Meet-the-Expert Evening (all participants)
19:10-21:10 Banquet

July 12

Time Session Chairperson Speaker Title
8:30-10:00 5. Novel immunotherapy strategies: Beyond PD-1/PD-L1 Dr. Gainor
Dr. Nishikawa
Dr. Hiroyoshi Nishikawa
(National Cancer Center Research Institute)
Targeting immune suppressive network for novel cancer immunotherapy
Dr. Justin F. Gainor
(Massachusetts General Hospital)
TBD
Dr. Koji Tamada
(Yamaguchi University Graduate School of Medicine)
Revolution of CAR-T cell technology to develop next-generation cancer immunotherapy
10:00-10:20 Break
10:20-11:50 6. Primary and acquired mechanisms of resistance to immunotherapies Dr. Herbst
Dr. Udono
Dr. Kenji Chamoto
(Kyoto University)
The role of fatty acid oxidation in T cells in the synergistic effect with PD-1 blockade
Dr. Heiichiro Udono
(Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)
Metabolism of tumor infiltrating immune cells regulates anti-tumor immunity
Dr. Roy S. Herbst
(Yale Cancer Center)
Primary and acquired mechanisms of resistance to immunotherapies
11:50-12:50 Lunch
12:50-14:20 7. Tumor heterogeneity and circulating tumor DNA Dr. Diehn
Dr. Yano
Dr. Seiji Yano
(Cancer Research Institute of Kanazawa University)
Heterogeneity of EMT and resistance mutation in ALK positive lung cancer
Dr. Maximilian Diehn
(Stanford University)
Circulating tumor DNA analysis for personalized cancer detection and monitoring
Dr. Tsukasa Kadota
(Research Institute, National Cancer Center)
Circulating microRNAs as biomarkers for predicting response to anti-programmed death 1 therapy in patients with non-small cell lung cancer (tentative)
14:20-14:40 Break
14:40-16:10 8. Tumor microenvironment and implications for treatment Dr. Miguel F. Sanmamed
Dr. Miyazono
Dr. Atsushi Enomoto
(Nagoya University Graduate School of Medicine)
Heterogeneity of cancer-associated fibroblasts and their functions in lung cancer (tentative)
Dr. Miguel F. Sanmamed
(Yale University)
Modeling patient-derived lung tumor microenvironment to develop immunotherapies
Dr. Kohei Miyazono
(The University of Tokyo)
Regulation of the development of lung cancer by TGF-beta signaling
16:10-16:20 Closing Remarks